Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Tourette syndrome (TS) is a complex neurodevelopmental disorder characterized by the occurrence of involuntary movements (motor tics) and vocalizations (phonic tics). The onset of TS is usually in childhood, and the prevalence of TS is estimated between 0.3 and 0.9% before the age of 18, decreasing progressively after that age. Most patients also suffer from associated psychiatric comorbidities (ADHD, OCD, mood disorders). Although the cause of TS remains unknown, the preferred hypothesis is the interaction of predisposing genetic factors and precipitating environmental factors (perinatal accidents, infectious diseases). From a pathophysiological point of view, it is widely demonstrated by structural, electrophysiological studies, functional neuroimaging, as well as by different animal models, that dysfunctions of the cortico-striato-pallido-thalamo-cortical loops (responsible for the regulation of movements, cognitive processes, and emotions) play a major role in the genesis of tics. Deep brain stimulation (DBS) treatment can be proposed as an invasive therapy in patients with severe TS resistant to usual treatments (psychotherapy, pharmacological treatments). In a well-selected population of drug-resistant patients, DBS allows an estimated overall improvement of 30 to 50% in the YGTSS score. The deep brain stimulation method currently used in TS is based on continuous (24/7) and undifferentiated stimulation (fixed electrical intensity). This stimulation paradigm, devoid of adaptability to the patient's symptoms, could be at the origin of undesirable effects (related to the modulation of physiological signals), of a sub-optimal efficiency, or of an unnecessary overuse of the stimulator's capacities (battery depletion). The development of new deep brain stimulation paradigms ("closed-loop stimulation"), allowing the identification of pathological neuronal activity and the dynamic adaptation of stimulation parameters to these neuronal signals, requires reliable and reproducible pathological biomarker, correlated with the occurrence of tics.
However, in TS, electrophysiological abnormalities are still not well characterized, and most of the work published on the subject were based on intraoperative recordings and needs to be confirmed on recordings at a distance from the surgery before its potential use in closed-loop stimulation paradigms. Indeed, during the first weeks after surgery, different factors tend to modify the electrophysiological signals.
Several questions arise at the end of this healing period:
In order to specify these biomarker(s), their temporal correlation to tic occurrence, their spatial distribution, as well as the dynamics and cortico-subcortical coherence of the identified abnormalities, we propose a prospective study on 10 patients with severe and drug-resistant TS, treated by bi-pallidal deep brain stimulation as part of routine care (no device implantation as part of the research).
An evaluation of pallidal LFP synchronized with a high-resolution video-electroencephalography recording (128 to 256 sensors) will be performed at a distance (M+[3-48]) from surgery, in order to determine the variations in pallidal and electroencephalographic activity surrounding the occurrence of tics. A control condition with voluntary ("tic-like") movement will be carried out in a second time, to distinguish the modifications related to the voluntary movement from those related to the occurrence of a tic. A reconstruction of the electrode positioning will be performed using the LeadDBS pipeline, and individual and group analyses will be performed to specify the mapping of pathological oscillations within the pallidum and throughout the cerebral cortex.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Patient with Tourette's syndrome | Experimental | Patient with Tourette's syndrome receiving deep brain stimulation treatment with implantation of the PERCEPTâ„¢ device as part of their medical management. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Multimodal electrophysiological recordings | Other | Intervention(s): Multimodal electrophysiological recordings (Local field potentials, High-Resolution Electroencephalogram, Electromyogram) coupled with video analysis, in experimental condition, in uncontrolled tic and voluntary ("tic-like") movement. |
| Measure | Description | Time Frame |
|---|---|---|
| Spectral power | Pallidal spectral power in the 2 clinical conditions (i) Tic [pre-tic-post] and (ii) Voluntary ("tic-like") movement [pre-movement-post] respectively. | Inclusion visit |
| Measure | Description | Time Frame |
|---|---|---|
| Electrode localization | Inclusion visit | |
| Pallidal and cortical spectral power | Pallidal and cortical spectral power analysis in the 2 clinical conditions (i) Tic and (ii) Voluntary movement ("tic-like"). |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Edouard COURTIN, Dr | Contact | 05 57 82 12 42 | edouard.courtin@chu-bordeaux.fr |
| Name | Affiliation | Role |
|---|---|---|
| Edouard COURTIN, Dr | University Hospital, Bordeaux | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| CHU de Bordeaux | Recruiting | Bordeaux | 33076 | France |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D005879 | Tourette Syndrome |
| ID | Term |
|---|---|
| D001480 | Basal Ganglia Diseases |
| D001927 | Brain Diseases |
| D002493 | Central Nervous System Diseases |
| D009422 | Nervous System Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| Inclusion visit |
| Pallidal and cortical time-frequency | the 2 clinical conditions (i) Tic and (ii) Voluntary movement ("tic-like"). | Inclusion visit |
| Cortico-subcortical coherence | Cortico-subcortical coherence of the recorded oscillations. | Inclusion visit |
| Cortico-subcortical phase synchronization | Cortico-subcortical phase synchronization of the recorded oscillations. | Inclusion visit |
| Cortico-subcortical phase-amplitude coupling | Cortico-subcortical phase-amplitude coupling of the recorded oscillations. | Inclusion visit |
| Adult ADHD Self-Report Scale (ASRS) Score | Used to assess symptoms of Attention-Deficit/Hyperactivity Disorder (ADHD) in adults, it consists of 18 items. Total score of 0 to 14: Low probability of ADHD. Total score of 15 to 24: Intermediate probability that the person exhibits symptoms of ADHD. Total score of 25 to 36: Suggests a high probability of ADHD. | Inclusion visit |
| Adult ADHD Self-Report Scale (ASRS) Score | Used to assess symptoms of Attention-Deficit/Hyperactivity Disorder (ADHD) in adults, it consists of 18 items. Total score of 0 to 14: Low probability of ADHD. Total score of 15 to 24: Intermediate probability that the person exhibits symptoms of ADHD. Total score of 25 to 36: Suggests a high probability of ADHD. | One month before inclusion |
| Yale-Brown Obsessive Compulsive Scale (Y-BOCS) Score | Considered as the reference scale for evaluating obsessive-compulsive disorders. Yale-Brown Obsessive Compulsive Scale (Y-BOCS) is designed to assess both the types of symptoms and their severity. The Y-BOCS evaluates 10 items, each rated from 0 (no symptoms) to 4 (extreme symptoms). The total score ranges as follows: 0 to 7: Normal 8 to 15: Mild 16 to 23: Moderate 24 to 31: Severe 32 to 40: Very severe | Inclusion visit |
| Yale-Brown Obsessive Compulsive Scale (Y-BOCS) Score | Considered as the reference scale for evaluating obsessive-compulsive disorders. Yale-Brown Obsessive Compulsive Scale (Y-BOCS) is designed to assess both the types of symptoms and their severity. The Y-BOCS evaluates 10 items, each rated from 0 (no symptoms) to 4 (extreme symptoms). The total score ranges as follows: 0 to 7: Normal 8 to 15: Mild 16 to 23: Moderate 24 to 31: Severe 32 to 40: Very severe | One month before inclusion |
| Yale Global Tic Severity Scale (YGTSS) Score | semi-structured clinical interview scale that is considered the gold standard for assessing the severity of tics in both children and adults. The YGTSS evaluates the number, frequency, intensity, complexity, and distress associated with motor and vocal tics over the past week. Each domain is assessed on a 6-point scale (from 0 to 5), with a separate, more global score for "overall disability" concerning the individual's daily life and activities. Five sub-scores can be extracted: The total "motor tic" score (from 0 to 25) The total "vocal tic" score (from 0 to 25) The total "tic" score (sum of the two previous scores) The overall disability assessment (one item; from 0 to 50) The global severity score (from 0 to 100) | Inclusion visit |
| Yale Global Tic Severity Scale (YGTSS) Score | semi-structured clinical interview scale that is considered the gold standard for assessing the severity of tics in both children and adults. The YGTSS evaluates the number, frequency, intensity, complexity, and distress associated with motor and vocal tics over the past week. Each domain is assessed on a 6-point scale (from 0 to 5), with a separate, more global score for "overall disability" concerning the individual's daily life and activities. Five sub-scores can be extracted: The total "motor tic" score (from 0 to 25) The total "vocal tic" score (from 0 to 25) The total "tic" score (sum of the two previous scores) The overall disability assessment (one item; from 0 to 50) The global severity score (from 0 to 100) | One month before inclusion |
| D013981 | Tic Disorders |
| D009069 | Movement Disorders |
| D020271 | Heredodegenerative Disorders, Nervous System |
| D019636 | Neurodegenerative Diseases |
| D030342 | Genetic Diseases, Inborn |
| D009358 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities |
| D065886 | Neurodevelopmental Disorders |
| D001523 | Mental Disorders |